Session » Vasculitis - Poster II: ANCA-Associated Vasculitis

Date: Monday, November 14, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1923

Activated Partial Thromboplastin Time Reflects Disease Activity in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1937

Analysis of Innate and Adaptive Immune Responses in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)

9:00AM-11:00AM: Abstract Number: 1950

ANCA-Associated Vasculitides and IgG4-Related Disease: An Overlapping Syndrome? a European Observational Study of 18 Patients

9:00AM-11:00AM: Abstract Number: 1946

Antineutrophil Cytoplasmic Antibody (ANCA) Type and Body Mass Index in ANCA-Associated Vasculitis (AAV)

9:00AM-11:00AM: Abstract Number: 1938

Bronchiectasis Are Highly Prevalent in Anti-MPO ANCA-Associated Vasculitis and Associate with a Distinct Disease Phenotype

9:00AM-11:00AM: Abstract Number: 1936

Clinical Characteristics of Inflammatory Eye Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1954

Clinical Features and Long Term Outcome of 105 Patients of Granulomatosis with Polyangiitis: A Single Centre Experience from North India

9:00AM-11:00AM: Abstract Number: 1924

Clinical Features and Outcome in Patients with Elderly Onset ANCA Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1929

Comparison of Two Different ANCA Iif Methods with EIA and Disease Phenotype

9:00AM-11:00AM: Abstract Number: 1934

Cutaneous Manifestations of ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1945

Development and Validation of Case-Finding Algorithms for the Identification of Patients with ANCA-Associated Vasculitis and Large-Vessel Vasculitis in Healthcare Administrative Databases

9:00AM-11:00AM: Abstract Number: 1944

Disease Activity, Glucocorticoid Exposure, and Rituximab Determine Body Composition Changes during Induction Treatment of ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1948

Evaluation of Body Composition Parameters in Granulomatosis with Polyangiitis: Association of Fat Mass Parameters with Disease Activity and Inflammatory Markers

9:00AM-11:00AM: Abstract Number: 1930

Factors Associated with Glucocorticoid Exposure in ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1943

Factors Predictive of ANCA-Associated Vasculitis Relapse

9:00AM-11:00AM: Abstract Number: 1940

High Prevalence of Inflammatory Heart Disease in Eosinophillic Granulomatosis with Polyangiitis (Churg Strauss) Patients

9:00AM-11:00AM: Abstract Number: 1935

Hypertrophic Pachymeningitis in a Population with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Study in a Single Japanese Institution

9:00AM-11:00AM: Abstract Number: 1939

Immunologic, Clinical and Demographic Correlates in 51 Cocaine Users with Serum Anti-Neutrophil Cytoplasmic Antibodies

9:00AM-11:00AM: Abstract Number: 1926

Indications for Testing and Diagnostic Outcome in Patients with Positive ANCA at a Canadian Tertiary Care Centre

9:00AM-11:00AM: Abstract Number: 1925

Interest of Procalcitonin for the Follow-up of ANCA-Associated Vasculitis: Data from a Cohort of 99 Patients

9:00AM-11:00AM: Abstract Number: 1952

Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 1933

M2 Macrophage Is the Predominant Phenotype in Airways Inflammatory Lesions in Patients with Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 1953

Management and Outcomes of ANCA-Associated Vasculitis in Unselected Cases within a Large Health Region of England

9:00AM-11:00AM: Abstract Number: 1931

MRI Findings in Granulomatosis with Polyangiitis: Pachymeningitis and Implications in Quality of Life

9:00AM-11:00AM: Abstract Number: 1947

Ocular Manifestations of ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1951

Phenotypic and Functional Perturbations of Peripheral B and T Lymphocytes in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

9:00AM-11:00AM: Abstract Number: 1932

Precapillary Pulmonary Hypertension in Granulomatosis with Polyangiitis: A Case Series with Long-Term Follow-up

9:00AM-11:00AM: Abstract Number: 1942

Presentation and Clinical Features of ANCA-Associated Vasculitis in US African Americans: Experience from a Single Center

9:00AM-11:00AM: Abstract Number: 1949

Presentation, Prognosis and Clinical-Pathological Correlations of Cutaneous Manifestations in ANCA-Associated Vasculitides

9:00AM-11:00AM: Abstract Number: 1927

Relapses in Patients with ANCA-Associated Vasculitis: A Retrospective Study on Severity and Organ Involvement Compared to Initial Onset

9:00AM-11:00AM: Abstract Number: 1941

Retrospective Survey of Concomitant Autoimmune Diseases and Autoantibodies in a Cohort of Patients with ANCA-Associated Vasculitis (AAV)

9:00AM-11:00AM: Abstract Number: 1928

Treatment of ANCA Associated Vasculitis in the Very Elderly

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].